A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
Primary Objective: Confirm the safety and feasibility of fedratinib maintenance following allogeneic HCT for patients with MPNs. Secondary Objectives: Determine the efficacy of fedratinib maintenance after allogeneic HCT in MPN patients defined as progression free survival (PFS) at 1 year following transplant. Tertiary Objectives: Characterize the pharmacokinetics of fedratinib given as a maintenance therapy after allogeneic HCT.
Chemotherapy (NOS); Therapy (NOS)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.